{"groups":[{"description":"On Day 1 of each 21-day cycle, participants received ramucirumab drug product (DP) followed by docetaxel. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\n* Ramucirumab DP: 10 milligrams per kilogram (mg/kg) administered intravenously.\n* Docetaxel: 75 milligrams per square meter (mg/m\\^2) (60 mg/m\\^2 for the countries of Korea and Taiwan only, with protocol amendment dated 22 May 2012) administered intravenously.","id":"FG000","title":"Ramucirumab and Docetaxel"},{"description":"On Day 1 of each 21-day cycle, participants received placebo followed by docetaxel. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\n* Placebo (matching Ramucirumab DP): 10 mg/kg administered intravenously.\n* Docetaxel: 75 mg/m\\^2 (60 mg/m\\^2 for the countries of Korea and Taiwan only, with protocol amendment dated 22 May 2012) administered intravenously.","id":"FG001","title":"Placebo and Docetaxel"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"341"},{"groupId":"FG001","numSubjects":"429"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"94"},{"groupId":"FG001","numSubjects":"55"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"90"},{"groupId":"FG001","numSubjects":"53"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"42"},{"groupId":"FG001","numSubjects":"45"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"37"},{"groupId":"FG001","numSubjects":"19"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}],"type":"Sponsor Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"9"}],"type":"Protocol Criterion Not Met and Deviation"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"628"},{"groupId":"FG001","numSubjects":"625"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"624"},{"comment":"Three participants randomized to placebo and docetaxel received 1 dose of ramucirumab in error.","groupId":"FG001","numSubjects":"621"}],"type":"Received Any Quantity of Any Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"14"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"613"},{"groupId":"FG001","numSubjects":"611"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants who died, due to any cause, or were alive at the end of the study but off study drug were considered to have completed the study."}